Arcus Biosciences (RCUS) Capital Expenditures (2017 - 2025)

Arcus Biosciences' Capital Expenditures history runs 9 years deep, the most recent figure standing at $1.0 million for Q4 2025.

• On a quarterly basis, Capital Expenditures rose 116.67% year-over-year to $1.0 million in Q4 2025; TTM through Mar 2026 was $1.0 million, a 104.55% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 109.09% from the prior year.
• Capital Expenditures steadied at $1.0 million in Q4 2025 per RCUS's latest filing, from $1.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $12.0 million in Q4 2023 and bottomed at -$20.0 million in Q3 2024.
• The 5-year median for Capital Expenditures is $2.0 million (2022), against an average of $764705.9.
• Biggest YoY gain for Capital Expenditures was 1232.06% in 2021; the steepest drop was 4298.65% in 2021.
• Year by year, Capital Expenditures stood at -$1.6 million in 2021, then jumped by 224.61% to $2.0 million in 2022, then jumped by 500.0% to $12.0 million in 2023, then sank by 150.0% to -$6.0 million in 2024, then jumped by 116.67% to $1.0 million in 2025.
• Per Business Quant, the three latest RCUS Capital Expenditures figures stand at $1.0 million (Q4 2025), $1.0 million (Q1 2025), and -$6.0 million (Q4 2024).